Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$36.85
+3.9%
$31.81
$25.17
$37.12
$6.14B0.312.24 million shs904,516 shs
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$8.70
+1.3%
$9.11
$6.00
$11.31
$2.21B0.575.05 million shs606,409 shs
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$32.14
-0.4%
$31.78
$18.47
$35.79
$2.52B0.98921,620 shs98,376 shs
Geron Corporation stock logo
GERN
Geron
$1.42
+1.8%
$1.58
$1.04
$2.01
$907.75M0.6816.68 million shs9.31 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+1.37%+6.26%+6.32%+2.16%+17.65%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-0.46%-6.64%-10.25%+30.99%-14.03%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-4.97%-0.09%+0.12%+31.06%+76.10%
Geron Corporation stock logo
GERN
Geron
+0.36%-12.03%-16.77%-14.20%+17.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$36.85
+3.9%
$31.81
$25.17
$37.12
$6.14B0.312.24 million shs904,516 shs
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$8.70
+1.3%
$9.11
$6.00
$11.31
$2.21B0.575.05 million shs606,409 shs
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$32.14
-0.4%
$31.78
$18.47
$35.79
$2.52B0.98921,620 shs98,376 shs
Geron Corporation stock logo
GERN
Geron
$1.42
+1.8%
$1.58
$1.04
$2.01
$907.75M0.6816.68 million shs9.31 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+1.37%+6.26%+6.32%+2.16%+17.65%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-0.46%-6.64%-10.25%+30.99%-14.03%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-4.97%-0.09%+0.12%+31.06%+76.10%
Geron Corporation stock logo
GERN
Geron
+0.36%-12.03%-16.77%-14.20%+17.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.82
Moderate Buy$45.2122.69% Upside
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2.75
Moderate Buy$20.70138.07% Upside
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.80
Moderate Buy$48.0049.37% Upside
Geron Corporation stock logo
GERN
Geron
2.00
Hold$2.5076.68% Upside

Current Analyst Ratings Breakdown

Latest GERN, ALKS, CLDX, and BCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Boost Price TargetOverweight$45.00 ➝ $48.00
5/7/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Boost Price TargetMarket Outperform$25.00 ➝ $28.00
5/7/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Lower Price TargetOutperform$22.00 ➝ $21.00
5/6/2026
Alkermes plc stock logo
ALKS
Alkermes
Boost Price TargetBuy$42.00 ➝ $48.00
5/6/2026
Alkermes plc stock logo
ALKS
Alkermes
Boost Price TargetOverweight$43.00 ➝ $44.00
5/6/2026
Alkermes plc stock logo
ALKS
Alkermes
Boost Price TargetBuy$45.00 ➝ $50.00
5/6/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Lower Price TargetBuy$18.00 ➝ $16.00
4/27/2026
Alkermes plc stock logo
ALKS
Alkermes
UpgradeHold (C)Hold (C+)
4/27/2026
Geron Corporation stock logo
GERN
Geron
Reiterated RatingSell (E+)
4/27/2026
Alkermes plc stock logo
ALKS
Alkermes
UpgradeStrong SellHold
4/20/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Reiterated RatingSell (D-)
(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.48B4.16$1.76 per share20.90$11.02 per share3.34
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$874.84M2.53$1.25 per share6.96($0.57) per share-15.25
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$1.54M1,637.84N/AN/A$7.93 per share4.05
Geron Corporation stock logo
GERN
Geron
$183.88M4.94N/AN/A$0.35 per share4.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$241.66M$0.9040.9554.20N/A9.78%9.26%5.66%7/28/2026 (Estimated)
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$263.86M-$1.78N/A14.99N/A-51.71%-76.36%60.12%N/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%N/A
Geron Corporation stock logo
GERN
Geron
-$83.50M-$0.11N/A14.15N/A-35.48%-23.31%-10.08%N/A

Latest GERN, ALKS, CLDX, and BCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million
5/6/2026Q1 2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million
5/6/2026Q1 2026
Geron Corporation stock logo
GERN
Geron
-$0.03-$0.01+$0.02-$0.01$50.59 million$51.84 million
2/26/2026Q4 2025
Alkermes plc stock logo
ALKS
Alkermes
$0.43$0.29-$0.14$0.29$380.44 million$384.55 million
2/26/2026Q4 2025
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$0.07$1.12+$1.05$1.12$151.32 million$163.28 million
2/25/2026Q4 2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$1.00-$1.22-$0.22-$1.22$1.53 million$0.12 million
2/25/2026Q4 2025
Geron Corporation stock logo
GERN
Geron
-$0.03-$0.05-$0.02-$0.05$50.43 million$48.02 million
2/14/2026Q4 2025
Alkermes plc stock logo
ALKS
Alkermes
N/A$0.29N/A$0.29N/A$384.55 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
Geron Corporation stock logo
GERN
Geron
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
0.85
2.27
1.70
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
1.91
1.88
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
8.92
8.92
Geron Corporation stock logo
GERN
Geron
0.52
6.78
4.96

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
85.88%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
Geron Corporation stock logo
GERN
Geron
73.71%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.59%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
5.10%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
5.20%
Geron Corporation stock logo
GERN
Geron
1.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,050166.68 million159.03 millionOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
530254.16 million241.20 millionOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
15078.49 million74.41 millionOptionable
Geron Corporation stock logo
GERN
Geron
70641.52 million630.55 millionOptionable

Recent News About These Companies

Is Geron (GERN) One of the Best US Stocks Under $5 to Buy?
Geron (NASDAQ:GERN) Issues Earnings Results
Geron: Q1 Earnings Snapshot
Geron Q1 Earnings Call Highlights
Geron (GERN) to Release Earnings on Wednesday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alkermes stock logo

Alkermes NASDAQ:ALKS

$36.85 +1.38 (+3.90%)
As of 11:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

BioCryst Pharmaceuticals stock logo

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.70 +0.12 (+1.34%)
As of 11:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$32.14 -0.15 (-0.45%)
As of 11:53 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Geron stock logo

Geron NASDAQ:GERN

$1.42 +0.03 (+1.80%)
As of 11:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.